- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
News Reports: Biden To Nominate Robert Califf To Be FDA Commissioner
Califf, who is described by some as a safe choice for the agency’s top job, headed the FDA during the last year of the Obama administration.
President Joe Biden is expected to announce later this morning that he will nominate Robert Califf, M.D., to be commissioner of the FDA, numerous news outlets are reporting.
Today’s news is not a surprise. Numerous news outlets reported several weeks ago that Califf had emerged as Biden’s top choice. The lack of permanent FDA has been conspicuous by its absence. If confirmed by the Senate, Califf would take over from Janet Woodcock, M.D., who has been acting commissioner since the beginning of the Biden administration.
Related: Why Doesn’t the FDA have a Permanent Commissioner?
This would be Califf’s second stint as FDA commissioner. He was commissioner during the last year of the Obama administration, serving from Feb. 24, 2016 through Jan. 20, 2017.
Politico broke the news that Califf would be nominated this morning just before 9 a.m.
The Wall Street Journal reported that some consumer advocacy groups, such as Public Citizen, have been pushing the administration not to nominate Califf because of his consulting experience with drugmakers.
The Washington Post said FDA experts see him as a “safe choice — an experienced hand who is unlikely to make abrupt changes.” The Post also reported that Califf is a senior adviser to Verily and Google Health.
FDA Site Inspections Decreased During Pandemic. Questions Continue about Drug Quality.
December 4th 2023A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
RSV Vaccines for Adults: Gaps in Understanding
December 4th 2023Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
